Evidence map›Paper›PMID 42233640›Full record

ReviewJournal of virology2026

Progress in enterovirus D68-neutralizing antibodies and vaccines.

Liting Wang, Jun Shen

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Liting WangDepartment of Infectious Disease, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.ORCID 0000-0001-7168-1585
Jun ShenDepartment of Infectious Disease, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.ORCID 0000-0002-8759-6921

Funding

Beijing Natural Science Foundation L242052Nantong Municipal Key Medical Discipline
6 · The paper itself

Abstract

Enterovirus D68 (EV-D68) causes severe respiratory diseases and acute flaccid myelitis (AFM), for which no licensed vaccines or therapeutics are currently available. Neutralizing antibodies (nAbs) block infection via binding capsid epitopes. This review summarizes the EV-D68 antigenic structure, nAb mechanisms (receptor blockade and conformational disruption), therapeutic prospects of nAbs, and vaccine progress (inactivated, virus-like particle [VLP], and nucleic acid). Key challenges, like antigenic drift and blood-brain barrier (BBB) penetration, are also highlighted to guide countermeasure development.

Indexed as

Antibodies, NeutralizingAntibodies, ViralEnterovirus D, HumanEnterovirus InfectionsViral VaccinesAnimalsBlood-Brain BarrierCentral Nervous System Viral DiseasesEpitopesHumansMyelitisNeuromuscular DiseasesVaccines, Virus-Like ParticleAntibodies, NeutralizingAntibodies, ViralEpitopesVaccines, Virus-Like ParticleViral Vaccinesacute flaccid myelitisantigenicityenterovirus D68neutralizing antibodyvaccine

Identifiers

PMID42233640
PMCPMC13289105

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.